Table 1.
Patient characteristics.
| Total (n = 1,274) | Progression (n = 36) | No progression (n = 1,238) | P-value | |
|---|---|---|---|---|
| Follow-up duration, months, median (range) | 18.3 (3.3–65.0) | 16.1 (7.1–40.5) | 18.5 (3.2–65.2) | 0.753 |
| Age at ICUS diagnosis, years, median (range) | 58.0 (44.0–69.0) | 59.5 (40.8–66.3) | 58.0 (44.0–69.0) | 0.512 |
| Age at censoring, years, median (range) | 62.0 (49.0–72.0) | 60.1 (43.0-68.3) | 62.0 (49.0–72.0) | 0.345 |
|
Sex, n (%) Male Female |
689 (54.1) | 24 (66.7) | 665 (53.7) | 0.124 |
| 585 (45.9) | 12 (33.3) | 573 (46.3) | ||
| WBC, × 103/µL, median (range) | 5.7 (3.7–8.6) | 3.7 (3.1–5.5) | 5.7 (3.8–8.7) | < 0.001 |
|
ANC, × 103/µL, median (range) <1,800, n (%) ≥1,800, n (%) |
2.9 (1.6–4.9) | 1.6 (0.8–2.8) | 3.0 (1.6–4.9) | < 0.001 |
| 300 (23.6) | 20 (55.6) | 280 (22.6) | < 0.001 | |
| 816 (64.1) | 16 (44.4) | 800 (64.6) | ||
| Monocytes, ×103/µL, median (range) | 0.41 (0.28–0.62) | 0.33 (0.18–0.45) | 0.41 (0.28–0.62) | 0.085 |
|
Hemoglobin, g/dL, median (range) < 13 (male) or 12 (female), n (%) ≥ 13 (male) or 12 (female), n (%) |
11.3 (9.4–12.8) | 10.3 (8.9–11.9) | 11.3 (9.4–12.9) | 0.005 |
| 892 (70.0) | 33 (91.7) | 859 (69.4) | 0.004 | |
| 382 (30.0) | 3 (8.3) | 379 (30.6) | ||
| MCV, fL, median (range) | 92.2 (88.0–97.3) | 99.9 (91.3–106.8) | 92.1 (87.9–97.0) | < 0.001 |
|
Platelet, × 103/µL, median (range) < 150, n (%) ≥ 150, n (%) |
122.5 (53.0–241.0) | 86.0 (51.9–205.0) | 126.0 (53.3–245.0) | 0.370 |
| 720 (56.5) | 21 (58.3) | 699 (56.5) | 0.823 | |
| 554 (43.5) | 15 (41.7) | 539 (43.5) | ||
| BM cellularity, %, median (range) | 35.0 (25.0–50.0) | 40.0 (25.0–55.0) | 35.0 (25.0–45.0) | 0.186 |
| BM blast, %, median (range) | 0.8 (0.4–1.57) | 1.2 (0.8–2.0) | 0.8 (0.4–1.4) | 0.019 |
ANC, absolute neutrophil count; BM, bone marrow; ICUS, idiopathic cytopenia of undetermined significance; MCV, mean corpuscular volume; WBC, white blood cell.